A phase I/II trial of nimodipine for HIV-related neurologic complications

Neurology

Volumn 51, Issue 1, 1998, Pages 221-228

  Navia, Bradford A ^a,b,i   Dafni, U ^d   Simpson, D ^e   Tucker, T ^f   Singer, E ^g   McArthur, J C ^h   Yiannoutsos, C ^d   Zaborski, L ^d   Lipton, S A ^b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ Research Laboratories in Psychiatry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NIMODIPINE;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NERVE INJURY; NEUROLOGICAL COMPLICATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0031814517     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.1.221     Document Type: Article

References (47)

1. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986;19:517-524.
2. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986;19:525-535.
3. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck A, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988;239:586-592.
4. Petito CK, Navia BA, Cho ES, et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;312:874-879.
5. Cornblath DR, McArthur JC, Kennedy PGE, et al. Inflammatory demyelinating peripheral neuropathies associated with human T cell lymphotropic virus type III infection. Ann Neurol 1987;21:32-40.
6. Griffin JW, Crawford TO, Glass JD, et al. Sensory neuropathy in AIDS: II. Immunopathology. Brain 1998 (in press).
7. Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319:1573-1578.
8. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-896.
9. Portegeis P, de Gans J, Lange JM, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989;299:819-821.
10. Gray F, Geny C, Dournon E, et al. Neuropathological evidence that zidovudine reduces the incidence of HIV infection of brain. Lancet 1991;337:852-853.
11. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo controlled trial. Ann Neurol 1992;33:343-349.
12. Glass J, Fedor H, Wesselingh SL, McArthur JC. Immunocyto-chemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995;38: 755-762.
13. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone M. Cellular localization of human immunodeficiency virus within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986;83:7089-7093.
14. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233:1089-1093.
15. Pumarola-Sune T, Navia BA, Cordon-Cardi C, Price RW. HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol 1987;21:490-496.
16. Brew B, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995;38:563-570.
17. Brennerman DE, Westbrook GL, Fitzgerald SP, et al. Neuronal cell killing by the envelope glycoprotein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988;355: 639-642.
18. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins of mononuclear phagocytes infected with HIV-1. Science 1990; 250:1593-1596.
19. Dreyer EB, Kaiser PK, Offermann IT, et al. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364-367.
20. Puliam L, Herndier BG, Tang NM, McGrath MS. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J Clin Invest 1991;87:503-512.
21. Lannuzel A, Liedo P-M, Lamghitnia HO, Vincent JD, Tardieu M. HIV-1 envelope proteins gp120 and gp160 potentiate NMDA-induced (Ca2+) increase, alter (Ca2+)i homeostasis and induce neurotoxicity in human embryonic neurons. Eur J Neurosci 1995;7:2285-2293.
22. Toggas S, Masliah E, Rockenstein E, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994;367:188-193.
23. Lipton S, Gendelman H. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332: 934-940.
24. Magnuson DSK, Knudson BE, Geiger JD, Brownstone RM, Nath A. Human immunodeficiency virus type tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995;37:373-380.
25. Adamson DC, Wildemann B, Sasaki M, et al. Immunologic NO synthase: elevation in severe AIDS dementia complex and induction by HIV-1 gp41. Science 1996;274:1917-1921.
26. Gelbard HA, Nottet HSL, Swindells S, et al. Platelet-activating factor: a candidate human immunodeficiency virus type-1 induced neurotoxin. J Virol 1994;68:4628-4635.
27. Wesselingh SL, Glass JD, Griffin JW, et al. Intracerebral cytokine expression in the brain during AIDS. Ann Neurol 1993; 33:576-589.
28. Jassoy C, Harrer T, Rosenthal T, et al. Human immunodeficiency virus type 1 specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha and beta when they encounter target antigens. J Virol 1993;67:2844-2852.
29. Yeung MC, Puliam L, Lau AS. The HIV envelope protein gp120 is toxic to human brain cell cultures through the induction of interleukin and tumor necrosis factor alpha. AIDS 1995;9:137-143.
30. Merrill IE, Koyagi Y, Zack J, et al. Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol 1992;66:2217-2225.
31. Muller WER, Schroder HC, Ushijima H, Dapper J, Bormann J. gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol 1992;226: 209-214.
32. Lipton SA. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 1992;42:1403-1405.
33. Neugebauer V, Vanegas H, Bebe J, Rjmenapp P, Schaible H-G. Effects of N- and L-type calcium channel antagonists on the responses of nociceptive spinal cord neurons to mechanical stimulation of the normal and inflamed knee joint. J Neurophysiol 1996;76:3740-3749.
34. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-1083.
35. Tross S, Price RW, Navia BA, et al. Neuropsychological characterization of the AIDS dementia complex: preliminary report. AIDS 1988;2:81-88.
36. Miller EN, Selnes OA, McArthur JC, et al. Neuropsychological performance in HIV-1 infected homosexual men: the Multicenter AIDS Cohort Study (MACS). Neurology 1990;40:197-203.
37. Selnes OA, Miller E, McArthur J, et al. HIV-1 infection: no evidence of cognitive decline during the asymptomatic stages. Neurology 1990;40:204-208.
38. Brew BJ, Bhalla RB, Fleisher M, et al. Cerebrospinal fluid B2 microglobulin in patients infected with human immunodeficiency virus. Neurology 1989;39:830-834.
39. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990;28:556-560.
40. McArthur JC, Nance-Sproson TE, Griffin DE, et al. The diagnostic utility of elevation in cerebrospinal fluid beta-2 micro-globulin in HIV-1 dementia. Neurology 1992;42:1707-1712.
41. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992;326:437-443.
42. Nordic Medical Research Councils HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992;304:13-17.
43. Rolinski B, Bogner JR, Sadfri I, et al. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid of HIV-1 infected patients. J AIDS Hum Retrovirol 1997;15:192-197.
44. Elovaara I, Poutiainen E, Lahdevirta J, et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch Neurol 1994;51:943-950.
45. Portegeis P, Enting R, De Gans J, et al. AIDS dementia complex and didanosine. Lancet 1994;344:759.
46. Sidtis JJ, Dafni U, Slasor P, et al. Stable neurologic function in subjects treated with 2′3′-dideoxyinosine. J Neurovirol 1997;3:233-240.
47. Hamer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.